| Literature DB >> 32627426 |
Celeste Manfredonia1,2, Manuele G Muraro2,3, Christian Hirt2,3, Valentina Mele1, Valeria Governa1,3, Adam Papadimitropoulos2, Silvio Däster4, Savas D Soysal4, Raoul A Droeser4, Robert Mechera4, Daniel Oertli4, Raffaele Rosso5, Martin Bolli6, Andreas Zettl7, Luigi M Terracciano8, Giulio C Spagnoli3, Ivan Martin2, Giandomenica Iezzi1,9.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related death. Conventional chemotherapeutic regimens have limited success rates, and a major challenge for the development of novel therapies is the lack of adequate in vitro models. Nonmalignant mesenchymal and immune cells of the tumor microenvironment (TME) are known to critically affect CRC progression and drug responsiveness. However, tumor drug sensitivity is still evaluated on systems, such as cell monolayers, spheroids, or tumor xenografts, which typically neglect the original TME. Here, it is investigated whether a bioreactor-based 3D culture system can preserve the main TME cellular components in primary CRC samples. Freshly excised CRC fragments are inserted between two collagen scaffolds in a "sandwich-like" format and cultured under static or perfused conditions up to 3 d. Perfused cultures maintain tumor tissue architecture and densities of proliferating tumor cells to significantly higher extents than static cultures. Stromal and immune cells are also preserved and fully viable, as indicated by their responsiveness to microenvironmental stimuli. Importantly, perfusion-based cultures prove suitable for testing the sensitivity of primary tumor cells to chemotherapies currently in use for CRC. Perfusion-based culture of primary CRC specimens recapitulates TME key features and may allow assessment of tumor drug response in a patient-specific context.Entities:
Keywords: 3D model; colorectal cancer; human tumor tissue culture; immune cells; perfusion bioreactor; tissue microenvironment
Mesh:
Substances:
Year: 2019 PMID: 32627426 DOI: 10.1002/adbi.201800300
Source DB: PubMed Journal: Adv Biosyst ISSN: 2366-7478